More Videos
SPECIAL REPORT
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- CNBC Anchor Takes a Sabbatical
- Privately Held Facebook Creates Dual-Class Stock
- NBA D-League On The Rise
- On Twitter, Beware False Prophets
- 10 Holiday Cocktail Recipes from Top Mixologists
- Just In Time for Holidays: More Gloom and Doom on Economy
- Oil Tomorrow
- Novartis 'Cells' Its Flu Vaccine Technology
- Citi Mortgage Reveals What Treasury Won't
- S&P to Hit 1,200 by Year-End: Chief Investor
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Facebook's Biggest-Ever Holiday Shopping Season
- Facebook's New Dual Class Structure - Slow Steps to an IPO
- 5 Big Bank Stocks Investors Should Consider: Strategists
- Gambling Drunk, Texting to Live And America's On Sale - Your Emails
- Nov. 24: Unusual Volume Leaders
- NBA D-League On The Rise
- US Firms Hit by Payroll Taxes at Exactly the Wrong Time
- Citi Mortgage Reveals Something the US Treasury Won't
- Fed Sanguine About US Recovery, Worried on Jobs
- Amended Berkshire Filing Reveals No 'Secret' Holdings
- In Time for Holidays: More Gloom and Doom on Economy
- Market Pros Reveal Top Black Friday Trades
- Turkey Day 101: How Well Do You Know Your Bird?
- Privately Held Facebook Creates Dual-Class Stock
- Holiday Guide to This Season's Smartphones
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
As promised, I will reveal the top-performing Nasdaq 100 stock of 2008--barring some 11th-hour stock-moving event in the last few days of the year.
The Nasdaq is down 42 percent this year. Its worst year ever. The Nasdaq biotech index has held up significantly better, but it still fell 16 percent.
And then there's Vertex Pharmaceuticals [VRTX
Loading...
()
]. As of Friday's close it was up 27 percent in 2008. The stock's been on a roller-coaster as investor sentiment swings back and forth over the perceived prospects for VRTX's drug for hepatitis C. So, I was surprised when I read our stock statistician's email last Friday evening pointing out that VRTX's 27 percent rise makes it the best performing stock in the Nasdaq 100 this year.
Vertex is in a race with Schering-Plough [SGP
Loading...
()
] to bring a good new drug for hep C to market. Investors could get another update on Vertex's progress when it presents at the JPMorgan Healthcare Conference in a few weeks.
As always, we'll be at the San Francisco event with a full lineup of live interviews with C-suite execs, including Vertex's Joshua Boger. I guess he'll get to take a victory lap for VRTX's whopping 70 percent outperformance of the Nasdaq this year.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes